X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   ACTAVIS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ACTAVIS
Dec-14
NATCO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs87717,677-   
Low Rs42410,783-   
Sales per share (Unadj.) Rs223.43,183.2-  
Earnings per share (Unadj.) Rs31.1-397.2-  
Cash flow per share (Unadj.) Rs40.3292.1-  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.56,904.3-  
Shares outstanding (eoy) m33.07265.90-   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.94.5 65.1%   
Avg P/E ratio x20.9-35.8 -58.4%  
P/CF ratio (eoy) x16.148.7 33.1%  
Price / Book Value ratio x3.02.1 143.7%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5043,783,778 0.6%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m1,1280-   
Avg. sales/employee Rs ThNM39,186.0-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-4,890.0-  
INCOME DATA
Net Sales Rs m7,389846,418 0.9%  
Other income Rs m167-2,112 -7.9%   
Total revenues Rs m7,556844,305 0.9%   
Gross profit Rs m1,793108,734 1.6%  
Depreciation Rs m304183,280 0.2%   
Interest Rs m36626,698 1.4%   
Profit before tax Rs m1,290-103,356 -1.2%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,582 0.0%   
Tax Rs m309-5,314 -5.8%   
Profit after tax Rs m1,027-105,624 -1.0%  
Gross profit margin %24.312.8 188.9%  
Effective tax rate %23.95.1 465.5%   
Net profit margin %13.9-12.5 -111.4%  
BALANCE SHEET DATA
Current assets Rs m3,681445,954 0.8%   
Current liabilities Rs m3,123325,231 1.0%   
Net working cap to sales %7.614.3 53.0%  
Current ratio x1.21.4 86.0%  
Inventory Days Days8958 154.2%  
Debtors Days Days5966 88.5%  
Net fixed assets Rs m7,685103,356 7.4%   
Share capital Rs m3310-   
"Free" reserves Rs m6,6700-   
Net worth Rs m7,2591,835,849 0.4%   
Long term debt Rs m955962,021 0.1%   
Total assets Rs m11,9573,364,507 0.4%  
Interest coverage x4.5-2.9 -157.5%   
Debt to equity ratio x0.10.5 25.1%  
Sales to assets ratio x0.60.3 245.6%   
Return on assets %11.7-2.3 -496.8%  
Return on equity %14.2-5.8 -246.0%  
Return on capital %20.7-3.0 -688.3%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Net fx Rs m2,7430-   
CASH FLOW
From Operations Rs m1,440145,346 1.0%  
From Investments Rs m-1,089-348,015 0.3%  
From Financial Activity Rs m-353195,534 -0.2%  
Net Cashflow Rs m-1-7,134 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.8 Rs / USD

Compare NATCO PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: FDC LTD.  BIOCON LTD  WYETH LTD  DISHMAN PHARMA  J.B.CHEMICALS  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views On News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 22, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS